Regeneron Pharmaceuticals Inc vs Ishares Msci Thailand Etf — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Ishares Msci Thailand Etf trades at $74.77. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Ishares Msci Thailand Etf pays none, and Ishares Msci Thailand Etf is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | THD | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $75.06 |
52-Week Low | $555.51 | $57.86 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
THD trades at $75.06, up 2.28% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings but faces selling pressure per ADX indicators. Recent news highlights THD's 38% annual returns driven by AI hardware exposure, though this creates vulnerability to profit-taking. Support levels cluster around $71-72 with resistance at $72-73.
Outlook remains cautious due to technical weakness and concentrated AI dependency. The dividend scheduled for June 2026 provides income support, but investors face rotation risks from Asian equities and Thailand's economic sensitivity to regional flows. Valuation metrics remain undisclosed in current data.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →